IF a sequential two-drug protocol of valproic acid (VPA; 1 mM, days 1–5) followed by CHIR99021 (3 µM, days 3–5, overlapping for final 3 days) is administered transiently to primary dermal fibroblasts isolated from aged (22–24 month) C57BL/6J male mice via culture medium supplementation,

THEN a measurable reversal of the Horvath-type DNA methylation epigenetic clock (target: ≥3–5 years equivalent murine epigenetic age reduction by RRBS-based murine methylation array), concurrent with retention of fibroblast identity markers (Vimentin+, FSP1+, absence of NANOG/OCT4 protein expression), will be observed within 5 days of treatment initiation compared to vehicle (DMSO)-treated aged fibroblast controls,

BECAUSE the following causal chain operates:

1. VPA, as a class I/II HDAC inhibitor, rapidly and robustly increases global histone H3 and H4 acetylation within 24–72 hours of exposure, broadly opening compacted chromatin associated with aging-related heterochromatin accumulation and epigenetic drift — a phenotype mechanistically analogous to the HDAC inhibitor panobinostat (LBH589) producing robust global H3/H4 acetylation increases and epigenetic pathway reactivation in primary progenitor cells (HDAC inhibition drives global acetylation and chromatin remodeling)[https://doi.org/10.1016/j.stemcr.2017.09.009].

2. This VPA-driven global chromatin decompaction creates a transient "epigenetic plasticity window" in which aging-locked CpG methylation patterns become accessible to endogenous demethylation machinery (TET enzymes), allowing reversal of aberrant hypermethylation at developmentally relevant promoters and hypomethylation at repetitive elements — both hallmarks of the advancing Horvath clock [SPECULATIVE: direct TET enzyme recruitment to VPA-opened chromatin in aged fibroblasts has not been directly demonstrated but is consistent with the mechanism of HDAC inhibitor-induced chromatin accessibility enabling de novo epigenetic editing].

3. Overlapping CHIR99021 treatment (days 3–5) activates Wnt/β-catenin signaling by inhibiting GSK3β, preventing β-catenin phosphorylation and degradation, and thus stabilizing nuclear β-catenin accumulation — a pathway demonstrated to facilitate replacement of transcription factors in direct reprogramming and somatic fate conversion without requiring pluripotency induction (Wnt–β-catenin activation facilitates transcription factor replacement in reprogramming)[https://doi.org/10.2147/sccaa.s38006].

4. Nuclear β-catenin, in the context of VPA-opened chromatin, acts as a co-activator at TCF/LEF target loci, specifically driving expression of proliferative and rejuvenation-associated gene programs (Myc targets, metabolic reprogramming genes, mitochondrial biogenesis factors) without reaching the threshold of pluripotency gene activation — because the VPA+CHIR cocktail lacks the p300/CBP inhibitory component (A-485) present in the 2C cardiac reprogramming protocol, preserving histone acetylation a...

SENS category: RepleniSENS

Key references: • doi.org/10.1016/j.stemcr.2017.09.009]. • doi.org/10.2147/sccaa.s38006]. • doi.org/10.1101/2023.10.24.563872]. • doi.org/10.5483/bmbrep.2016.49.5.045]. • doi.org/10.1101/2023.10.24.563872],